WebPembrolizumab. Pembrolízumàb, pod zaščitenim imenom Keytruda, je humanizirano monoklonsko protitelo, [3] ki se uporablja v imunoterapiji rakavih bolezni, in sicer melanoma, pljučnega raka, raka glave in vratu, hodgkinovega limfoma, [4] raka urotelija, raka ledvic in raka debelega črevesa. [5] Uporablja se v obliki intravenske injekcije. WebDescription: Pembrolizumab is a humanised immunoglobulin G4 monoclonal antibody which binds to the cell surface receptor programmed death-1 (PD-1), a negative immunoregulatory protein, and prevents it from interacting with ligands PD-L1 and PD-L2. Blockade of the PD-1 pathway results in the reactivation of tumour specific cytotoxic T ...
Pembrolizumab monotherapy - UpToDate
WebFood and Drug Administration WebPembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.. Common side effects include fatigue, musculoskeletal pain, … duo orpheo
Food and Drug Administration
WebPembrolizumab injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on September 24, 2024). … WebKEYTRUDA is not chemotherapy or radiation therapy—it is an immunotherapy and it works with your immune system to help fight cancer. KEYTRUDA can cause your immune system to attack normal organs … WebJun 27, 2024 · Indications. Pembrolizumab is an FDA-approved monoclonal antibody directed against programmed cell death protein 1 (PD-1) and sold in the US. It initially received FDA accelerated approval for refractory, advanced melanoma in September 2014. Subsequently, it has received approval for the treatment of many other oncologic … cryptantha rostellata